Bristol Myers Squibb, via its subsidiary RayzeBio, will invest over $173 million. This expands operations in central Indiana. The project includes a new 450,000-square-foot facility in Whitestown's Anson Industrial Park.
The expansion aims to increase production capacity for next-generation radiopharmaceutical therapies (RPTs). These therapies deliver targeted radiation to cancer cells. The investment expects to create up to 100 new, high-wage jobs by the end of 2029. Construction on the new facility begins this year. This move underscores BMY's commitment to expanding its infrastructure in the growing field of radiopharmaceuticals. BMY acquired RayzeBio in 2024.